Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

PubMed for BioSystems (Select 198784)

1.

STAT3 and cardiac remodeling.

Haghikia A, Stapel B, Hoch M, Hilfiker-Kleiner D.

Heart Fail Rev. 2011 Jan;16(1):35-47. doi: 10.1007/s10741-010-9170-x. Review.

PMID:
20407820
2.

MicroRNA: novel regulators involved in the remodeling and reverse remodeling of the heart.

Wang J, Xu R, Lin F, Zhang S, Zhang G, Hu S, Zheng Z.

Cardiology. 2009;113(2):81-8. doi: 10.1159/000172616. Epub 2008 Nov 19.

PMID:
19018142
3.

The Wnt/frizzled/GSK-3 beta pathway: a novel therapeutic target for cardiac hypertrophy.

Blankesteijn WM, van de Schans VA, ter Horst P, Smits JF.

Trends Pharmacol Sci. 2008 Apr;29(4):175-80. doi: 10.1016/j.tips.2008.01.003. Epub 2008 Mar 14. Review.

PMID:
18342376
4.

MicroRNA-133 controls cardiac hypertrophy.

Carè A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MV, Høydal M, Autore C, Russo MA, Dorn GW 2nd, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, Condorelli G.

Nat Med. 2007 May;13(5):613-8. Epub 2007 Apr 29.

PMID:
17468766
5.

Regulation of cardiac hypertrophy by intracellular signalling pathways.

Heineke J, Molkentin JD.

Nat Rev Mol Cell Biol. 2006 Aug;7(8):589-600. Review.

PMID:
16936699
6.

The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice.

Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng CF, Kitsis RN, Molkentin JD.

EMBO J. 2000 Dec 1;19(23):6341-50.

7.

Calcineurin and beyond: cardiac hypertrophic signaling.

Molkentin JD.

Circ Res. 2000 Oct 27;87(9):731-8. Review.

8.

Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy.

Takeishi Y, Ping P, Bolli R, Kirkpatrick DL, Hoit BD, Walsh RA.

Circ Res. 2000 Jun 23;86(12):1218-23.

9.

Small guanine nucleotide-binding proteins and myocardial hypertrophy.

Clerk A, Sugden PH.

Circ Res. 2000 May 26;86(10):1019-23. Review.

10.

The PI3K-PDK1 connection: more than just a road to PKB.

Vanhaesebroeck B, Alessi DR.

Biochem J. 2000 Mar 15;346 Pt 3:561-76. Review.

11.

Signal transduction during cardiac hypertrophy: the role of G alpha q, PLC beta I, and PKC.

Jalili T, Takeishi Y, Walsh RA.

Cardiovasc Res. 1999 Oct;44(1):5-9. Review. No abstract available.

12.

Prevention of cardiac hypertrophy by calcineurin inhibition: hope or hype?

Olson EN, Molkentin JD.

Circ Res. 1999 Apr 2;84(6):623-32. Review. No abstract available.

13.

Calcineurin and human heart failure.

Lim HW, Molkentin JD.

Nat Med. 1999 Mar;5(3):246-7. No abstract available.

PMID:
10086361
14.

A calcineurin-dependent transcriptional pathway for cardiac hypertrophy.

Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN.

Cell. 1998 Apr 17;93(2):215-28.

15.
16.

Cardiotrophin-1 and the role of gp130-dependent signaling pathways in cardiac growth and development.

Wollert KC, Chien KR.

J Mol Med (Berl). 1997 Jul;75(7):492-501. Review.

PMID:
9253712
17.

Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways.

Wollert KC, Taga T, Saito M, Narazaki M, Kishimoto T, Glembotski CC, Vernallis AB, Heath JK, Pennica D, Wood WI, Chien KR.

J Biol Chem. 1996 Apr 19;271(16):9535-45.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk